Company intelligence / Profile preview

Kingdom Therapeutics

Ownership: Private
Development stage: Other

Overview

The company has presented key pre-clinical results at a major ASD conference (Synchrony) in California and is investigating if their drug KT-20610 can improve both behavioral and gastrointestinal symptoms in ASD[1]

Therapeutic areas: GastroenterologyPsychiatry
Modalities: Cannabinoid-based therapeutics
Industry: Biotech

Drug pipeline

1 asset

KT-20610

Unknown

Partnerships

Founding member of the Cannabinoid Research & Development Group UK (CRDG)[1]

Beyond the preview

Go deeper on Kingdom Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kingdom Therapeutics.